<DOC>
	<DOCNO>NCT02923726</DOCNO>
	<brief_summary>The primary objective understand role antitachycardia pacing ( ATP ) primary prevention patient indicate ICD therapy program accord current guidance high rate cut-offs therapy delay . The time first all-cause shock test subject standard therapy ( ATP shock ) compare subject program shock ass equivalency .</brief_summary>
	<brief_title>Assessment Primary Prevention Patients Receiving An ICD - Systematic Evaluation ATP</brief_title>
	<detailed_description />
	<mesh_term>Death</mesh_term>
	<mesh_term>Death , Sudden , Cardiac</mesh_term>
	<criteria>Subject Boston Scientific transvenous ICD ( de novo implant upgrade pacemaker ICD ) implant one following : Prior MI leave ventricular ejection fraction ( LVEF ) less equal ( ≤ ) 30 % OR Ischemic nonischemic cardiomyopathy , LVEF ≤ 35 % , New York Heart Association ( NYHA ) class II III Subject age 21or , consider legal age per give geography Subject willing capable providing inform consent Subject willing capable comply followup visit define protocol History spontaneous sustain Ventricular Tachycardia ( VT ) ( ≥ 160 bpm ≥ 30 second duration ) Ventricular Fibrillation ( VF ) due reversible cause NYHA Class IV document medical record within 90 calendar day prior enrollment Subject eligible schedule cardiac resynchronization ( CRT ) implant Subjects previous subcutaneous ICD ( SICD ) Subject exist TVICD device implant great 60 day Subjects coronary artery bypass graft surgery percutaneous coronary intervention within past 90 calendar day prior enrollment Subjects document myocardial infarction within past 90 calendar day prior enrollment Subjects active heart transplant list Subject ventricular assist device ( VAD ) receive VAD Life expectancy shorter 18 month due medical condition ( e.g. , cancer , uremia , liver failure , etc… ) Subjects currently require hemodialysis Subject know pregnant plan become pregnant course trial Subject enrol concurrent clinical study , exception local mandatory governmental registry observational studies/registries , without write approval Boston Scientific</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Antitachycardia Pacing Therapy</keyword>
	<keyword>Shock Therapy</keyword>
	<keyword>Primary Prevention</keyword>
</DOC>